Upcoming Events

Join global regulators, industry, and academia to engage in a series of strategic discussions on current regulatory landscape, globalization, and harmonization initiatives in Latin America.

Register now

Dedicated to the delivery of safe, effective and commercially viable CAR, and TCR immunotherapies for liquid and solid tumours.

Join the minds from large pharma, biotech, and academia who are striving to harmonize the European regulatory process, streamline manufacturing, and optimize CAR-T targets and constructs for solid tumours.

Covering the full pharmaceutical value chain from discovery through to commercialization, this meeting will equip you with the lessons learned to overcome the glass ceiling in manufacture, safety management, and patient accessibility. This year the meeting will span 4 full days including 9 discussion-based strategic dives, 2 full summit days with 3 focused tracks of content, followed by two focus day agendas. This tracked agenda provides a platform for the European community to come together, whilst ensuring you have meaningful conversations with those facing the same challenges as you.

Register now

Discover pragmatic case studies of machine learning in action to augment your processes for increased efficiency & accuracy from target discovery to phase 2 clinical trials.

The 3rd Annual AI-ML: Drug Discovery & Development Summit is the industry’s definitive guide to translating the wealth of tech available to successful, efficacious, and efficient R&D processes. With 3 days of real-world case studies, this summit will provide the roadmap to augmented R&D decision making with reduced failure rates, increased speed, and improved margins.

This year’s summit will take a deeper look at:

• Target, pathway, and molecule selection — identifying which will treat individual disease indications better

• Predictive preclinical models – knowing from the beginning how drug candidates will react when administered to in vivo and in vitro models

• Identification of the patients who will react best to the treatment with minimal side effects for a guaranteed successful clinical trial

Join 80+ like-minded peers from the likes of Genentech, Novartis, Takeda, Teva Pharmaceuticals, The Broad Institute of MIT & Harvard, Recursion Pharmaceuticals, and many more to overhaul R&D and reflect on the lessons learned from the successes and mistakes made from a year of implementation and utilization.

Walk away with a blueprint for more accurate, more efficient, and more effective R&D processes.

Download the Full Event Guide to get a taste of the real-world case studies you’ll be joining at the conference.

Register now

MIT invites you to attend the 18th annual MIT Sloan Healthcare and BioInnovations Conference (SHBC) on February 27-28, 2020 at the MIT Media Lab.

This year’s theme is Patient-Centric Medicine. MIT will explore issues surrounding the improvement of care delivery through novel treatments, personalization, and system optimization. The conference will look to provide perspectives from across the healthcare landscape that shed light on how thought leaders are tackling these issues to shape the future of medicine.

Attendees will enjoy hearing from 30+ speakers, panelists, and keynotes from industry luminaries to serial entrepreneurs. You will also have the opportunity to see MIT’s most promising start-ups compete for $20K+ in prize money, learn about cutting-edge research from MIT PhDs, and form connections across the broader healthcare community.

Register now

The last day of February has been designated as Rare Disease Day in Massachusetts to call attention to the public health issues associated with rare diseases, which affect nearly 30 million Americans and countless others around the world. The event recognizes Rare Disease Day and the research being done in Massachusetts to treat and cure rare disease.

This year’s agenda will feature two panels: one from the patient perspective on how they’ve turned their diagnoses into their life’s work, finding empowerment through advocacy and action; and one from the industry’s perspective on how researchers and providers are not only tailoring a therapy for a specific patient but also the entire patient experience, and how this outlook has shaped their careers.

Alone we are rare, together we are strong.

Register now